J Wöllner1, J Krebs2, J Pannek1. 1. Neuro-Urology, Swiss Paraplegic Center, Nottwil, Switzerland. 2. Clinical Trial Unit, Swiss Paraplegic Center, Nottwil, Switzerland.
Abstract
STUDY DESIGN: This is a retrospective chart analysis. OBJECTIVES: The objective of this study was to evaluate the effect of sacral neuromodulation (SNM) in patients with neurogenic lower urinary tract dysfunction (NLUTD). SETTINGS: This study was conducted in a spinal cord injury rehabilitation center in Switzerland. METHODS: The charts of all patients who underwent SNM (testing and/or permanent implantation) because of NLUTD at our institution between 2007 and 2013 were evaluated. Treatment outcomes and complications were recorded. RESULTS: A total of 50 patients, 30 women and 20 men, with a mean age of 46 (±14) years, fulfilled the inclusion criteria. The most frequent cause for SNM was spinal cord injury in 35 patients (70%). Median duration of the underlying disease was 9.5 (±9.3) years. In all, 35 patients (70%) received a permanent implant. The complication rate was 16% (8/50). At the last follow-up, SNM was in use in 32 patients. In 26 patients with SNM because of detrusor overactivity, voiding frequency per 24 h was significantly reduced from 9 to 6, and daily pad use rate was significantly improved (2.6 versus 0.6 pads per 24h). On comparing urodynamic assessment of detrusor function before and under SNM, no significant suppression of neurogenic detrusor overactivity (NDO) was detected. In nine patients with chronic neurogenic urinary retention, median postvoid residual urine was significantly reduced from 370 to 59 ml. In all, 94% of the patients were either very satisfied or satisfied with SNM. CONCLUSION: SNM might be an additional therapy option in carefully selected patients with NLUTD. On the basis of our results, urodynamic evaluation before SNM is mandatory, as the procedure does not seem to be suited to significantly alleviate NDO.
STUDY DESIGN: This is a retrospective chart analysis. OBJECTIVES: The objective of this study was to evaluate the effect of sacral neuromodulation (SNM) in patients with neurogenic lower urinary tract dysfunction (NLUTD). SETTINGS: This study was conducted in a spinal cord injury rehabilitation center in Switzerland. METHODS: The charts of all patients who underwent SNM (testing and/or permanent implantation) because of NLUTD at our institution between 2007 and 2013 were evaluated. Treatment outcomes and complications were recorded. RESULTS: A total of 50 patients, 30 women and 20 men, with a mean age of 46 (±14) years, fulfilled the inclusion criteria. The most frequent cause for SNM was spinal cord injury in 35 patients (70%). Median duration of the underlying disease was 9.5 (±9.3) years. In all, 35 patients (70%) received a permanent implant. The complication rate was 16% (8/50). At the last follow-up, SNM was in use in 32 patients. In 26 patients with SNM because of detrusor overactivity, voiding frequency per 24 h was significantly reduced from 9 to 6, and daily pad use rate was significantly improved (2.6 versus 0.6 pads per 24h). On comparing urodynamic assessment of detrusor function before and under SNM, no significant suppression of neurogenic detrusor overactivity (NDO) was detected. In nine patients with chronic neurogenic urinary retention, median postvoid residual urine was significantly reduced from 370 to 59 ml. In all, 94% of the patients were either very satisfied or satisfied with SNM. CONCLUSION: SNM might be an additional therapy option in carefully selected patients with NLUTD. On the basis of our results, urodynamic evaluation before SNM is mandatory, as the procedure does not seem to be suited to significantly alleviate NDO.
Authors: Werner Schäfer; Paul Abrams; Limin Liao; Anders Mattiasson; Francesco Pesce; Anders Spangberg; Arthur M Sterling; Norman R Zinner; Philip van Kerrebroeck Journal: Neurourol Urodyn Date: 2002 Impact factor: 2.696
Authors: Y Akkoç; M Ersöz; N Yıldız; B Erhan; R Alaca; H Gök; M Zinnuroğlu; Z A Özçete; H Tunç; K Kaya; E Alemdaroğlu; M Sarıgül; S Konukçu; B Gündüz; A N Bardak; S Özcan; Y Demir; S Güneş; K Uygunol Journal: Spinal Cord Date: 2012-10-30 Impact factor: 2.772
Authors: Karl-Dietrich Sievert; Bastian Amend; G Gakis; P Toomey; A Badke; H P Kaps; Arnulf Stenzl Journal: Ann Neurol Date: 2010-01 Impact factor: 10.422
Authors: M A Schiefer; M Freeberg; G J C Pinault; J Anderson; H Hoyen; D J Tyler; R J Triolo Journal: J Neural Eng Date: 2013-08-05 Impact factor: 5.379
Authors: Jeffrey D Redshaw; Sara M Lenherr; Sean P Elliott; John T Stoffel; Jeffrey P Rosenbluth; Angela P Presson; Jeremy B Myers Journal: BMC Urol Date: 2018-08-29 Impact factor: 2.264
Authors: Elena E Keller; Irina Patras; Ioan Hutu; Karin Roider; Karl-Dietrich Sievert; Ludwig Aigner; Günter Janetschek; Lukas Lusuardi; Reinhold Zimmermann; Sophina Bauer Journal: Neurourol Urodyn Date: 2019-12-23 Impact factor: 2.696